Literature DB >> 10998026

Preventive treatment of intranasal fluticasone propionate reduces cytokine mRNA expressing cells before and during a single nasal allergen provocation.

A Kleinjan1, A F Holm, M D Dijkstra, S S Boks, L Severijnen, P G Mulder, W J Fokkens.   

Abstract

BACKGROUND: The local production and release of a number of cytokines regulate allergic upper airway inflammation. Medication is usually used at the presentation of the first symptoms. There are, however, clues that it is advisable to start taking the corticosteroid before the grass pollen season begins.
METHODS: This single allergen provocation study was conducted in autumn, out of the hay fever season. Nasal mucosa biopsies were taken twice before provocation (before and after 4 weeks of preventive treatment) and three times after allergen provocation (1 h, 24 h and 1 week). The preventive treatment used was fluticasone propionate aqueous nasal spray (FPANS) (n = 10) or a placebo (n = 9). Eosinophils and mRNA positive cells (in situ hybridization for IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IFNgamma, RANTES and TNFalpha) were counted in the biopsies.
RESULTS: Preventive treatment with FPANS out of season resulted in a decrease in eosinophils and mRNA positive cells for IL-5 and IL-6. After allergen provocation, levels of most of the measured cytokines (IL-3, IL-5, IL-6, IL-13, IFNgamma, RANTES and TNFalpha) and eosinophils were reduced using corticosteroids. The numbers of cells (eosinophils, IL-3, IL-6 and IL-8) correlated with nasal symptoms. Significant correlations in the early and late allergic phase were found between eosinophils and cytokines (IL-3, IL-10 and IL-13).
CONCLUSION: These results indicate that preventive treatment with FPANS prior to contact with grass pollen is effective in reducing the increase of cytokine mRNA positive cells in reaction to grass pollen contact.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998026     DOI: 10.1046/j.1365-2222.2000.00904.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  6 in total

Review 1.  Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies.

Authors:  Manuel A R Ferreira
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

Review 2.  Evidence-based treatment of allergic rhinitis.

Authors:  R Pawankar; W Fokkens
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.806

Review 3.  Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies.

Authors:  G W Canonica; E Compalati
Journal:  Clin Exp Immunol       Date:  2009-08-25       Impact factor: 4.330

Review 4.  Therapeutic targets in rhinosinusitis: infection or inflammation?

Authors:  Valerie J Lund
Journal:  Medscape J Med       Date:  2008-04-29

5.  In vitro effects of fluticasone propionate on IL-13 production by mitogen-stimulated lymphocytes.

Authors:  Gabriele Di Lorenzo; Maria Luisa Pacor; Maria Esposito Pellitteri; Sebastiano Gangemi; Patrizia Di Blasi; Giuseppina Candore; Alfredo Colombo; Domenico Lio; Calogero Caruso
Journal:  Mediators Inflamm       Date:  2002-06       Impact factor: 4.711

6.  IL-17 expression in dermatitis herpetiformis and bullous pemphigoid.

Authors:  Agnieszka Zebrowska; Malgorzata Wagrowska-Danilewicz; Marian Danilewicz; Olga Stasikowska-Kanicka; Anna Cynkier; Anna Sysa-Jedrzejowska; Elzbieta Waszczykowska
Journal:  Mediators Inflamm       Date:  2013-07-21       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.